BACK TO TOP
KSE100
165,867.31
-2288.18
(-1.36%)
KSE100PR
49,970.41
-699.15
(-1.38%)
ALLSHR
100,415.11
-1406.14
(-1.38%)
KSE30
49,518.47
-633.14
(-1.26%)
KMI30
237,511.28
-3182.77
(-1.32%)
BKTI
46,185.33
-610.99
(-1.31%)
OGTI
33,929.38
-432.76
(-1.26%)
KMIALLSHR
65,024.26
-881.93
(-1.34%)
PSXDIV20
76,229.20
-967.08
(-1.25%)
UPP9
59,412.61
-725.44
(-1.21%)
NITPGI
44,268.37
-505.99
(-1.13%)
NBPPGI
47,355.01
-647.68
(-1.35%)
MZNPI
29,810.73
-336.78
(-1.12%)
JSMFI
41,950.22
-880.37
(-2.06%)
ACI
21,084.59
-378.78
(-1.76%)
JSGBKTI
69,751.21
-1090.04
(-1.54%)
HBLTTI
19,154.31
02-10-2026
18.54
(0.10%)
MII30
21,513.98
-262.35
(-1.20%)
BF Biosciences Limited
PHARMACEUTICALS
Rs.122.45
-2.23
(-1.79%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Mon, Oct 5, 2026 3:46 PM
REG
DFC
CSF
ODL
Open
124.68
High
125.59
Low
122.00
Volume
27,252
CIRCUIT BREAKER
112.21 — 137.15
DAY RANGE
122.00 — 125.59
52-WEEK RANGE ^
117.20 — 177.99
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
124.68
VAR
11.50
HAIRCUT
15.00
P/E Ratio (TTM) **
17.10
1-Year Change * ^
-24.04%
YTD Change * ^
-12.86%

No record found

Last update: Sun, Aug 30, 2026 3:51 AM
Open
0.00
High
0.00
Low
0.00
Close
0.00
Change
0.00%
LDCP
127.62
Volume
0
Total Trades
0
CIRCUIT BREAKER
114.86 — 140.38
DAY RANGE
0.00 — 0.00
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
Last update: Sun, Aug 2, 2026 2:52 AM
Open
0.00
High
0.00
Low
0.00
Close
0.00
Change
0.00%
LDCP
126.09
Volume
0
Total Trades
0
CIRCUIT BREAKER
113.48 — 138.70
DAY RANGE
0.00 — 0.00
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.

KEY PEOPLE
Muhammad Farhan RafiqCEO
Sebastian Martin FerrarassiChairperson
Abdur RehmanCompany Secretary
ADDRESS

197-A, The Mall, Rawalpindi, Pakistan

WEBSITE

www.bfbio.com

REGISTRAR

CDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi

AUDITOR

KPMG Taseer Hadi & Co. Chartered Accountants

Fiscal Year End

June

Equity Profile

Market Cap (000's)
10,816,416.75
Shares
88,333,334
Free Float
26,500,000
Free Float
30.00%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Sep 29, 2026Financial Results for the Year Ended 2026-06-30 View   PDF
Apr 30, 2026Transmission of Quarterly Report for the Period Ended 31-03-2026 View   PDF
Apr 28, 2026Financial Results for the Quarter Ended 31-03-2026 View   PDF
Apr 17, 2026Half Yearly Progress Report - For the Period Ended 31 December 2025 View   PDF
Feb 27, 2026Transmission of Quarterly Financial Statements for the Period Ended 31-12-2025 View   PDF
DateTitleDocument
Sep 21, 2026Board Meeting View   
Jul 6, 2026Board Meeting Other Than Financial Results View   
Apr 20, 2026Board Meeting View   
Feb 18, 2026Board Meeting View   
Dec 22, 2025Decisions of Emergent Board of Directors Meeting Held On Dec 19, 2025 View   PDF
DateTitleDocument
Aug 20, 2026Material Information View   PDF
Jul 14, 2026Approval of Annual Budget for FY 2026-27 View   
Jun 9, 2026Appointment of Director to Fill Casual Vacancy View   PDF
Jun 2, 2026Intimation of Passing Away of Mrs. Akhter Khalid Waheed, Director and Founding CEO View   PDF
Jun 1, 2026Appointment of Director to Fill Casual Vacancy View   PDF

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
20262025
Sales9,461,2535,837,466
Profit after Taxation632,127447,147
EPS7.165.52
Q3 2026Q2 2026Q1 2026Q3 2025
Sales2,135,4912,668,1252,432,2941,500,469
Profit after Taxation117,646187,782159,521124,527
EPS1.332.131.811.59
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

2026202520242023
Gross Profit Margin (%)43.2039.1941.89
Net Profit Margin (%)6.687.6610.53
EPS Growth (%)29.71(9.36)
PEG0.67(3.27)

Payouts

Financial Reports